SIR-2501

N/A

Report date: 2026/05/13 17:57:38
NME

Base Information

Drug NameSIR-2501
Drug Alias NameSIR-2501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD(+) hydrolase SARM1 inhibitors
TargetsNAD(+) hydrolase SARM1
Therapy Area/IndicationsNerve DegenerationPeripheral Nervous System DiseasesNeurodegenerative Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSironax Aus Pty Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSironax Aus Pty LtdSironax (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNerve DegenerationPeripheral Nervous System DiseasesNeurodegenerative Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A